within Pharmacolibrary.Drugs.ATC.A;

model A06AD15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.001,
    Cl             = 3e-05,
    adminDuration  = 600,
    adminMass      = 17000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A06AD15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Macrogol, also known as polyethylene glycol (PEG), is an osmotic laxative used primarily for the treatment of constipation, particularly chronic idiopathic constipation and for bowel preparation prior to colonoscopy. It is approved and widely used today as a safe and effective laxative.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for healthy adult subjects; macrogol (PEG 3350) is minimally absorbed after oral administration.</p><h4>References</h4><ol><li><p>Sherstoboev, EY, et al., &amp; Madonov, PG (2022). Pharmacokinetic Parameters of Oral Pegylated IFN-λ1. <i>Bulletin of experimental biology and medicine</i> 173(2) 215–218. DOI:<a href=\"https://doi.org/10.1007/s10517-022-05521-3\">10.1007/s10517-022-05521-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35737159/\">https://pubmed.ncbi.nlm.nih.gov/35737159</a></p></li><li><p>Kaklotar, D, et al., &amp; Muthu, MS (2016). Transition from passive to active targeting of oral insulin nanomedicines: enhancement in bioavailability and glycemic control in diabetes. <i>Nanomedicine (London, England)</i> 11(11) 1465–1486. DOI:<a href=\"https://doi.org/10.2217/nnm.16.43\">10.2217/nnm.16.43</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27171572/\">https://pubmed.ncbi.nlm.nih.gov/27171572</a></p></li><li><p>Rao, S, &amp; Prestidge, CA (2016). Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery. <i>Expert opinion on drug delivery</i> 13(5) 691–707. DOI:<a href=\"https://doi.org/10.1517/17425247.2016.1151872\">10.1517/17425247.2016.1151872</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26866382/\">https://pubmed.ncbi.nlm.nih.gov/26866382</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A06AD15;
